Dr Reddy's Bosutinib US launch wins 180-day exclusivity

Launch announcement and what it signals

Dr. Reddy’s Laboratories has announced the launch of Bosutinib Tablets 400 mg in the United States, expanding its oncology portfolio in the market. The product is a generic equivalent of Pfizer’s Bosulif, a therapy used in chronic myeloid leukemia (CML). The company described the launch as a first-to-file (FTF) initiative for the 400 mg strength, which makes it eligible for 180 days of generic drug exclusivity in the US. The update was carried by Business Wire and also referenced in a regulatory filing to stock exchanges. Dr. Reddy’s said the introduction is aimed at improving timely access to essential therapies for patients and healthcare professionals.

Product positioning: generic alternative to Bosulif

Bosutinib is positioned as an oral tyrosine kinase inhibitor used in CML. The referenced indication states Bosulif (bosutinib) is used in the US for newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). It is also indicated for adult patients with chronic, accelerated, or blast phase Ph+ CML who show resistance or intolerance to prior therapy. The material also notes that a 400 mg tablet strength was approved in addition to previously approved 100 mg and 500 mg strengths. For newly diagnosed patients, the recommended dose cited is 400 mg orally once daily with food. For patients resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy, the recommended dose cited is 500 mg orally once daily with food.

First-to-file status and 180-day generic exclusivity

Dr. Reddy’s said Bosutinib Tablets 400 mg qualify as an FTF product and are eligible for 180 days of generic exclusivity in the US for this dosage. In practical terms, such exclusivity typically provides an early window where limited generic competition is expected, subject to regulatory and market conditions. The company’s communication highlights this as a key feature of the launch. Dr. Reddy’s also framed the product’s introduction as part of its broader objective of prompt market access for important therapies.

Partnership with MSN Laboratories: roles and responsibilities

The company has collaborated with Hyderabad-based MSN Laboratories Private Limited for the Bosutinib product. Under the arrangement, Dr. Reddy’s holds exclusive marketing rights in the United States. MSN is responsible for the development and manufacturing of the product. This structure separates commercial execution from manufacturing and development responsibilities, with Dr. Reddy’s leading the US market push for the 400 mg tablets.

Reference market size: Bosulif US sales data

To provide context on the branded product’s market footprint, the report cites IQVIA National Sales Perspectives data showing Pfizer’s Bosulif recorded sales of approximately $153.8 million in the United States for the 12-month period ended April 2026. While generic launches do not directly translate into the same level of sales, the cited figure indicates the scale of the branded reference product in the US market. Dr. Reddy’s has not commented on pricing for its generic Bosutinib 400 mg.

Brand pricing context cited for the 400 mg strength

The report notes that Pfizer’s Bosulif 400 mg dosage form is listed at a wholesale cost of about $11,495 to $11,740 for a bottle of 30 tablets in the US. This number is presented as a reference point for the branded medicine’s listed wholesale level. Dr. Reddy’s has not disclosed the price for its generic version in the same update.

Regulatory and product record details mentioned

The material includes a product listing for REDDY-BOSUTINIB under Dr. Reddy’s Laboratories Ltd., showing DIN: 02560011, Status: Approved, and Status date: 2025-08-11. The active ingredient is listed as bosutinib (bosutinib dihydrate) with a strength of 400 mg. Separately, the US indication summary referenced notes that bosutinib was first approved in September 2012, and that the 400 mg tablet strength was recently approved in addition to earlier strengths.

Financial snapshot included alongside the update

Alongside the US launch context, the material references Dr. Reddy’s quarterly performance update: Q1FY26 revenues were ₹14,700 million, representing 11% year-on-year growth and 13% quarter-on-quarter growth. It also states that during the quarter the company launched five new products in the US and filed one new Abbreviated New Drug Application (ANDA) with the USFDA. The same set of notes also mentions that Dr. Reddy’s launched Lenalidomide Capsules in the US, with two of six strengths eligible for first-to-market 180-day exclusivity.

Key facts table

Company and media contacts shared

The update includes contact points for investors and media. For Investor Relations, the contact listed is Aishwarya Sitharam (awaryitharamdrredd.com). For Media Relations, the contact listed is Priya K (priyaK@drreddys.com). These details were shared as part of the public communication around the launch.

Why the launch matters for Dr. Reddy’s US oncology pipeline

The Bosutinib launch adds to Dr. Reddy’s stated push to expand its oncology portfolio in the US. The combination of an FTF position and 180-day exclusivity for the 400 mg strength is highlighted as a differentiator for early market entry. The cited Bosulif sales data provides a clear reference point for the branded market size, while the wholesale cost range signals the high value of the therapy area. At the same time, the company has not provided pricing for its generic version, so the immediate revenue impact from this specific product is not quantified in the material provided.

Conclusion

Dr. Reddy’s has entered the US market with Bosutinib Tablets 400 mg, a generic equivalent of Pfizer’s Bosulif, and has stated it is eligible for 180 days of exclusivity as an FTF product. The product is being commercialised in partnership with MSN Laboratories, with Dr. Reddy’s holding exclusive US marketing rights and MSN handling development and manufacturing. Further details on pricing were not disclosed, and investors are likely to watch subsequent filings and commercial updates for more clarity on rollout and market uptake.